Acute leukemia is a fast-moving blood cancer in which the bone marrow produces large numbers of immature, nonfunctional blood cells called blasts. These blasts multiply rapidly, crowd out healthy cells, and cause the disease to worsen over days to weeks rather than months or years. There are two main types: acute myeloid leukemia (AML), which affects cells that would normally become certain white blood cells, red blood cells, or platelets, and acute lymphoblastic leukemia (ALL), which affects cells destined to become a different group of white blood cells called lymphocytes.
How It Develops in the Bone Marrow
Your bone marrow is a factory that constantly produces three types of blood cells: red blood cells (which carry oxygen), white blood cells (which fight infection), and platelets (which help blood clot). In acute leukemia, a genetic error causes one of these cell lines to get stuck at an early, immature stage. Instead of maturing into working blood cells, these blasts divide uncontrollably and begin to fill the marrow.
Bone marrow failure is actually a relatively late event in the disease’s progression. By the time symptoms appear, the leukemic cells have already begun suppressing normal blood cell production, either by physically crowding out healthy stem cells or by releasing chemical signals that reshape the marrow environment. The result is a predictable set of problems: too few red blood cells (anemia), too few functional white blood cells (leaving you vulnerable to infections), and too few platelets (causing abnormal bleeding).
Symptoms and How Quickly They Appear
Most people with acute leukemia first notice symptoms caused by this bone marrow failure rather than by the leukemia cells themselves. Common signs include:
- Fatigue and weakness from anemia
- Frequent or severe infections and fevers from a shortage of working white blood cells
- Easy bruising, nosebleeds, or tiny red spots on the skin (petechiae) from low platelet counts
- Unexplained weight loss
- Bone pain or tenderness, especially in the legs and sternum
- Swollen lymph nodes, enlarged liver, or enlarged spleen
These symptoms often develop over just a few weeks and tend to get worse noticeably. That rapid timeline is what separates acute leukemia from chronic forms, where symptoms can simmer for months or years before anyone notices.
AML vs. ALL
The distinction between AML and ALL comes down to which cell line is affected. AML arises from the myeloid line, the cells that normally mature into infection-fighting white blood cells, red blood cells, and platelets. ALL arises from the lymphoid line, which produces lymphocytes, a different branch of immune cells. Under a microscope, AML blasts are typically larger with more visible internal structure, while ALL blasts tend to be smaller and simpler in appearance.
ALL is the most common childhood cancer, with peak incidence between ages 2 and 5. AML is predominantly an adult disease, with the median age at diagnosis in the mid-60s. The distinction matters enormously for treatment because the two types respond to very different therapies.
Known Risk Factors
Most cases of acute leukemia arise without a clear cause, but several factors raise the risk. Ionizing radiation is one of the most well-established environmental triggers. Studies of atomic bomb survivors showed increased rates of both ALL and chronic myeloid leukemia, and the risk varies by sex, age at exposure, and hormonal factors. Long-term exposure to benzene (found in some industrial settings and cigarette smoke) is another confirmed cause.
Prior cancer treatment can also play a role. Patients who received certain types of chemotherapy or radiation for an earlier cancer face a higher risk of developing what’s called therapy-related AML. Genetic mutations in the TP53 gene, a key tumor suppressor, appear in 30 to 40 percent of therapy-related cases compared to only 5 to 10 percent of cases that arise on their own. Some inherited conditions, including Down syndrome and certain rare genetic disorders, also increase susceptibility.
How It’s Diagnosed
Diagnosis starts with a blood test that reveals abnormal cell counts, but confirmation requires a bone marrow biopsy. During this procedure, you lie on your stomach or side while a doctor numbs a spot on the back of your hip. A hollow needle is inserted through the bone to withdraw a small amount of liquid marrow (the aspiration), followed by a slightly larger needle that removes a tiny core of solid marrow tissue (the biopsy). The whole procedure typically takes about 30 minutes, and most people describe a deep pressure sensation and brief sharp pain when the marrow is drawn.
A pathologist then examines the samples to determine the percentage of blast cells and their characteristics. For AML without specific genetic abnormalities, diagnosis generally requires at least 20% blasts in the marrow or blood. However, when certain genetic mutations are present, the threshold can be as low as 10%, and in some cases the latest classification systems allow diagnosis based on the genetic abnormality alone regardless of blast count. Specialized staining and antibody tests help distinguish AML from ALL and identify the exact subtype, which guides treatment decisions.
Treatment Phases
Treatment for acute leukemia follows a structured sequence designed to eliminate cancer cells in stages. The first phase, called induction, aims to destroy as many leukemia cells as possible and push the disease into remission. This phase involves intensive chemotherapy, usually given in a hospital over several weeks. The goal is to get blast counts in the marrow below detectable levels.
Once remission is achieved, consolidation therapy begins. This phase targets any remaining leukemia cells that survived induction, using additional rounds of chemotherapy that typically continue for several months. For some patients, a stem cell transplant is recommended during consolidation, particularly for those with high-risk genetic features or whose leukemia is likely to return.
A third phase, maintenance therapy, is standard for ALL but less commonly used in AML. Maintenance involves lower-dose oral medications taken for up to two years to keep the leukemia from coming back. Between these phases, the overall active treatment timeline can stretch from several months to more than two years.
Targeted Therapies
Beyond traditional chemotherapy, newer treatments attack leukemia cells based on their specific genetic mutations. In 2025, the FDA approved two drugs in a new class called menin inhibitors for adults with relapsed or hard-to-treat AML carrying a particular mutation in the NPM1 gene. These treatments work differently from standard chemotherapy by blocking a specific protein interaction that leukemia cells with this mutation depend on to survive.
Other targeted approaches include drugs that block proteins leukemia cells use to avoid normal cell death, antibody-based therapies that deliver toxins directly to cancer cells, and a treatment called CAR-T cell therapy that reprograms a patient’s own immune cells to hunt leukemia. Which options are available depends heavily on the genetic profile of the leukemia, making the initial molecular testing at diagnosis critical.
Survival Rates and Outlook
Survival varies significantly between AML and ALL, and within each type it depends on age, genetic subtype, and how well the leukemia responds to initial treatment. For AML, the overall five-year relative survival rate is about 33%, based on the most recent data from the National Cancer Institute covering 2015 through 2021. That number is an average across all ages, and it masks a wide range: younger adults with favorable genetic profiles can have cure rates above 60%, while older adults with high-risk mutations face much lower odds.
ALL has a markedly different survival landscape. Children with ALL now have five-year survival rates exceeding 90% in many subtypes, making it one of the great success stories in cancer treatment over the past several decades. Adults with ALL fare less well, though outcomes have improved with the addition of targeted and immune-based therapies. For both types, the speed of response to induction therapy is one of the strongest predictors of long-term outcome. Patients who achieve complete remission after the first round of treatment consistently do better than those who need additional cycles.